MAZE — Maze Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -115 | -100 | 52.2 | -131 |
| Depreciation | ||||
| Non-Cash Items | 15.2 | 15.8 | 21.9 | 19.1 |
| Unusual Items | ||||
| Equity in Net Earnings/Losses | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -3.24 | -6.32 | -1.52 | -2.27 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -99.2 | -86.8 | 76 | -112 |
| Capital Expenditures | -1.97 | -0.441 | -1.15 | -0.794 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -1.2 | 0 | — | -170 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -3.17 | -0.441 | -1.15 | -171 |
| Financing Cash Flow Items | — | — | -3.15 | 141 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 1.73 | 16.4 | 92.8 | 275 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -101 | -70.9 | 168 | -7.57 |